Home
Resources
Publications
Recent Advances in Managing HIV-associated Cryptococcal Meningitis

Recent Advances in Managing HIV-associated Cryptococcal Meningitis

Timothée Boyer-Chammard, Elvis Temfack, Alexandre Alanio, Joseph N Jarvis, Thomas S Harrison, Olivier Lortholary

F1000Res. 2019 May 28;8:F1000 Faculty Rev-743.

PMID: 31275560

Abstract:

The recent development of highly sensitive and specific point-of-care tests has made it possible to diagnose HIV-associated cryptococcal meningitis within minutes. However, diagnostic advances have not been matched by new antifungal drugs and treatment still relies on old off-patent drugs: amphotericin B, flucytosine and fluconazole. Cryptococcal meningitis treatment is divided in three phases: induction, consolidation and maintenance. The induction phase, aimed at drastically reducing cerebrospinal fluid fungal burden, is key for patient survival. The major challenge in cryptococcal meningitis management has been the optimisation of induction phase treatment using the limited number of available medications, and major progress has recently been made. In this review, we summarise data from key trials which form the basis of current treatment recommendations for HIV-associated cryptococcal meningitis.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP2022857-A	Flucytosine		2022-85-7	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: